Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02536261 : Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
AgesMin: 15 Years Max: 70 Years
Inclusion Criteria:

1. Aged between 15 and 70 years old, either sex;

2. Karnofsky performance status ? 70;

3. Patients who were suffered Invasive prolactinomas involving the cavernous sinus ,
referring to ?Serum prolactin level>200ng/ml, or >4000mIU/L;?enhanced Magnetic
Resonance images confirm tumor invasion into cavernous sinus, i.e. Knosp grade ? or
?, and were treated by dopamine agonists treatment;

4. PRL remains normal level for no less than two years;

5. Tumor volume has shrank more than 50%, and the distance is more than 5mm between
tumor and optical nerve;

6. The patient has signed the informed consent.

Exclusion Criteria:

1. Patients concomitantly taking the psychotropic drugs or other drugs causing elevated

2. Patients with parkinson disease and is taking dopaminergic agents;

3. Patients with prolactinoma who received Gamma knife treatment;

4. Patients who use any dopamine receptor agonists other than bromocriptine and

5. Patients taking the other prolactinomas simultaneously;

6. pregnant or lactating women, or women preparing pregnant;

7. Patients with poor compliance, who cannot implement the program strictly.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557